DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
DBV Technologies S.A.NASDAQ: DBVT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $400K (cash outflow) rose 3900.0% year over year, ahead of the -8.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3900.0% holds above the trailing-twelve-month pace of -8.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (533.64K) USD
- Year-over-year change
- +77.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (533.64K) | +77.2% |
| FY2024 | 2024-12-31 | (2.34M) | -245.8% |
| FY2023 | 2023-12-31 | (677K) | +10.2% |
| FY2022 | 2022-12-31 | (754K) | +17.9% |
| FY2021 | 2021-12-31 | (918K) | — |
Capital Expenditures vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 capital expenditures of $928K is the 4th largest of the 11 companies compared; the peer median is $426K.
- Its year-over-year change of -8.4% is the 4th highest of 9, against a peer median of -36.6%.
- Over three fiscal years its annual growth of -10.9% compares with a peer median of -38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.69M | +140168207.3% | — | 7.8% | |
| LTM Mar 2026 | $2.23M | -44.0% | -1.0% | 3.3% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $1.39M | +138.4% | +113.3% | — |
| LTM Mar 2026 | $928K | -8.4% | -10.9% | — | |
| LTM Mar 2026 | $556K | -70.3% | -68.0% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $432K | +50.0% | -23.9% | — |
| LTM Mar 2026 | $420K | -96.6% | -53.7% | 10.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $78K | — | — | — |
| LTM Mar 2026 | $63K | -29.2% | -72.4% | — | |
| LTM Mar 2026 | $42K | -92.6% | -3.1% | — | |
| LTM Mar 2026 | $32K | — | -55.6% | 88.9% | |
| Peer median (excluding DBVT) | $426K | -36.6% | -38.8% | 9.3% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.81M) | (96.27M) | (72.73M) | (113.92M) | (146.95M) |
| Depreciation & Amortization | 8.38M | 13.16M | (14M) | (925K) | 3.19M |
| Deferred Income Tax | 184K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.12M | 5.03M | 6.02M | 4.62M | 5.39M |
| Change in Working Capital | (22.77M) | 22.32M | 953K | 5.75M | 1.34M |
| Accounts Receivables | 2.15M | 0 | 0 | 0 | 0 |
| Inventory | (16.18M) | 0 | 0 | 0 | (16.11M) |
| Accounts Payables | (7.56M) | 3.46M | 8.42M | 272K | 15.83M |
| Other Working Capital | (1.19M) | 18.86M | (7.47M) | 5.48M | 1.62M |
| Other Non-Cash Items | 656K | 66K | 99K | (3K) | 15.84M |
| Operating Cash Flow | (108.24M) | (55.7M) | (79.65M) | (104.47M) | (121.18M) |
| Capital Expenditures | (918K) | (754K) | (677K) | (2.34M) | (533.64K) |
| Acquisitions (Net) | 511.01K | 7.61K | 0 | 0 | 0 |
| Purchases of Investments | (119K) | (123K) | (285K) | 0 | 0 |
| Sales of Investments | (511.01K) | 770K | 154K | 0 | 0 |
| Other Investing Activities | 604K | (611) | (131K) | 1.58M | (829.34K) |
| Investing Cash Flow | (433K) | (100K) | (808K) | (757K) | (1.37M) |
| Debt Repayment | (582.92K) | (474K) | 0 | 0 | 0 |
| Common Stock Issued | 978K | 194.59M | 6.92M | 634K | 277.04M |
| Common Stock Repurchased | 0 | 0 | (154K) | (47K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (121.08K) | (20K) | 0 | 0 | (854.56K) |
| Financing Cash Flow | 274K | 194.1M | 6.77M | 587K | 276.18M |
| Effect of Forex Changes | (10.65M) | (6.5M) | 5.87M | (4.27M) | 8.08M |
| Net Change in Cash | (119.05M) | 131.9M | (67.83M) | (108.91M) | 161.71M |
| Free Cash Flow | (109.16M) | (56.45M) | (80.33M) | (106.82M) | (121.18M) |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.